PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN’S LYMPHOMA: A COST-EFFECTIVENESS ANALYSIS